Retinal Vasculitis with Macular Edema After Immunosuppressant Therapy Has Not Controlled Inflammation
This protocol applies to a severe presentation of retinal vasculitis — one marked by significant loss of visual acuity, macular edema, and extensive retinal involvement — where prior immunosuppressant therapy has not achieved adequate suppression of intraocular inflammation.
Clinical scenario
Significant loss of visual acuity, macular edema, and extensive retinal involvement — the most severe end of the retinal vasculitis spectrum, requiring an escalated therapeutic approach.
Previous treatment — goals not reached
Immunosuppressant therapy — agents such as azathioprine, cyclosporine, cyclophosphamide, methotrexate, chlorambucil, mycophenolate mofetil, or tacrolimus — was used with the goal of suppressing intraocular inflammation. When that target is not achieved (noting that these agents may take up to three months to take effect), escalation to the next therapeutic step is indicated.
Next therapeutic approach (partial overview)
The approach at this stage involves immunobiological therapy. The full selection criteria, monitoring requirements, and sequencing are set out in the complete structured regimen.
References
DOI: 10.25259/JORP_34_2024
In the most severe cases, with significant loss of visual acuity, macular edema, and extensive retinal involvement, the use of systemic corticosteroid therapy (oral or intravenous) is indicated.
In most cases, treatment is performed with local or systemic corticosteroids in combination or without immunosuppressants and subsequently immunobiological therapy.
View source ↗